Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sarepta

- PMLiVE

EMA to review Bluebird’s blood disorder gene therapy

LentiGlobin could free patients of regular blood transfusions

- PMLiVE

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

News from pharma, biotech and healthcare

- PMLiVE

Mallinckrodt doses first patient in muscular dystrophy trial

Repurposed drug could help delay decline in muscle function

- PMLiVE

Sangamo bulks up in cell therapy with TxCell acquisition

Hopes to start cell-based immunotherapy trials next year

- PMLiVE

Pfizer enters late-stage haemophilia B gene therapy trial

Race is on to free patients of regular injections

AstraZeneca AZ

AZ makes gene therapy move with 4DMT alliance

The new partnership will focus on creating an AAV for lung disease

- PMLiVE

Axovant licenses another gene therapy as new strategy beds in

Group pursues gene therapy strategy

- PMLiVE

Summit plunges after Duchenne disappointment

UK company to abandon lead molecule after phase II trial failure

- PMLiVE

Sarepta soars on positive Duchenne data

Trial results position Sarepta as a “leader in the field” according to analysts

- PMLiVE

UK firm Nightstar bags FDA fast-track status for gene therapy

Its choroideremia disease candidate gets RMAT designation

- PMLiVE

AMICULUM boosts global healthcare communications offering with a new specialist agency, Seques®

AMICULUM is entering its 18th year of growth as an independent healthcare communications and consulting business. Today we are delighted to announce the launch of the first communications agency specializing...

AMICULUM

Biomarin

BioMarin ups the ante for pivotal haemophilia gene therapy trial

Adds another 90 patients to the GENEr8-1 registration study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links